New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 3, 2013
06:42 EDTREGN, SNYRegeneron acquires full rights to two novel development programs from Sanofi
Regeneron Pharmaceuticals (REGN) announced that it has expanded its ophthalmology portfolio by acquiring full exclusive rights to two families of novel antibodies invented at Regeneron and previously included in Regeneron's antibody collaboration with Sanofi (SNY). Regeneron acquired full rights to antibodies targeting the PDGF, or platelet derived growth factor, family of receptors and ligands in ophthalmology and all other indications and to antibodies targeting the ANG2 receptor and ligand in ophthalmology. Antibodies to PDGF and ANG2 are currently in preclinical development for use in ophthalmology. With respect to PDGF antibodies, Regeneron will pay Sanofi $10M upfront, up to $40M in development milestone payments, and royalties on sales. With respect to ANG2 antibodies in ophthalmology, Regeneron will pay Sanofi $10M upfront, a potential $5M development milestone payment, and royalties on sales.
News For REGN;SNY From The Last 14 Days
Check below for free stories on REGN;SNY the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 31, 2014
14:22 EDTSNY, REGNSanofi, Regeneron announce results from four Phase 3 ODYSSEY trials
Subscribe for More Information
13:59 EDTREGNRW Baird to hold a conference
Subscribe for More Information
13:41 EDTREGNCitigroup to hold a conference
Subscribe for More Information
12:50 EDTSNY, REGNEuropean Society of Cardiology to hold a conference
Subscribe for More Information
August 29, 2014
12:23 EDTREGN, SNYNovartis drug data to be presented this weekend
Subscribe for More Information
10:06 EDTSNYSanofi unit treatment of Fabry's disease granted orphan status
Subscribe for More Information
08:18 EDTSNYPerrigo among companies showing interest in Omega Pharma, Bloomberg says
Subscribe for More Information
August 25, 2014
12:19 EDTSNYOn The Fly: Midday Wrap
Subscribe for More Information
11:48 EDTREGN, SNYSanofi and Regeneron co-host a conference call
Subscribe for More Information
10:40 EDTSNYBiotechs rise after InterMune acquired by Roche
Subscribe for More Information
August 22, 2014
12:39 EDTSNYThese five companies will benefit from increased ALS awareness, MarketWatch says
A recent surge in funding for Lou Gehrig's disease, or ALS, caused by the Ice Bucket challenge that is widespread on social media outlets, will benefit five pharmaceutical companies that are involved in the development of a cure for ALS, according to MarketWatch. The companies that are or have been involved in developing a treatment for ALS include Biogen Idec (BIIB), Avanir Pharmaceuticals (AVNR), Isis Pharmaceuticals (ISIS), Sanofi (SNY), and Bristol-Myers Squibb (BMY), MarketWatch added. Reference Link
August 21, 2014
05:42 EDTSNYIllumina announces strategic partnership with AstraZeneca, Sanofi, Janssen
Illumina (ILMN) announced it has formed collaborative partnerships with leading pharmaceutical companies to develop a universal next-generation sequencing, or NGS,-based oncology test system. The system will be used for clinical trials of targeted cancer therapies with a goal of developing and commercializing a multi-gene panel for therapeutic selection, resulting in a more comprehensive tool for precision medicine. Initial strategic partners include AstraZeneca (AZN), Janssen Biotech, a Johnson & Johnson (JNJ) company, and Sanofi (SNY). Illumina is working with the strategic partners to develop assays that detect and measure multiple variants simultaneously to support partners’ clinical trials, with the objectives of securing regulatory agency approvals and test commercialization. In parallel, Illumina is working with key thought leaders to set standards for NGS-based assays in routine clinical oncology practice, as well as to define regulatory frameworks to enable this new testing paradigm. Together, Illumina and its strategic partners aim to transition from single-analyte companion diagnostics to panel-based assays that select for “companion therapeutics.”
August 19, 2014
16:46 EDTSNYFDA approves Genzyme Cerdelga capsules
Subscribe for More Information
August 18, 2014
07:57 EDTREGNCambridge Healthtech Institute to hold a summit
6th Annual Bioprocessing Summit to be held in Boston on August 18-22.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use